X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs AUROBINDO PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER AUROBINDO PHARMA PFIZER/
AUROBINDO PHARMA
 
P/E (TTM) x 24.2 18.0 134.5% View Chart
P/BV x 3.8 5.8 65.8% View Chart
Dividend Yield % 0.8 0.4 237.4%  

Financials

 PFIZER   AUROBINDO PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-16
AUROBINDO PHARMA
Mar-16
PFIZER/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,7241,541 176.8%   
Low Rs1,611582 276.8%   
Sales per share (Unadj.) Rs440.9237.5 185.7%  
Earnings per share (Unadj.) Rs48.733.9 143.8%  
Cash flow per share (Unadj.) Rs75.840.6 186.7%  
Dividends per share (Unadj.) Rs15.002.50 600.0%  
Dividend yield (eoy) %0.70.2 293.8%  
Book value per share (Unadj.) Rs462.9120.6 383.9%  
Shares outstanding (eoy) m45.75585.17 7.8%   
Bonus/Rights/Conversions -PREF-  
Price / Sales ratio x4.94.5 110.0%   
Avg P/E ratio x44.531.3 142.1%  
P/CF ratio (eoy) x28.626.2 109.4%  
Price / Book Value ratio x4.78.8 53.2%  
Dividend payout %30.87.4 417.3%   
Avg Mkt Cap Rs m99,163621,041 16.0%   
No. of employees `0002.913.3 21.7%   
Total wages/salary Rs m2,75815,508 17.8%   
Avg. sales/employee Rs Th6,981.710,457.6 66.8%   
Avg. wages/employee Rs Th954.51,167.1 81.8%   
Avg. net profit/employee Rs Th771.11,491.6 51.7%   
INCOME DATA
Net Sales Rs m20,170138,961 14.5%  
Other income Rs m8571,663 51.6%   
Total revenues Rs m21,028140,624 15.0%   
Gross profit Rs m4,31032,056 13.4%  
Depreciation Rs m1,2393,926 31.6%   
Interest Rs m52,568 0.2%   
Profit before tax Rs m3,92327,225 14.4%   
Minority Interest Rs m039 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,7947,444 24.1%   
Profit after tax Rs m2,22819,820 11.2%  
Gross profit margin %21.423.1 92.6%  
Effective tax rate %45.727.3 167.3%   
Net profit margin %11.014.3 77.4%  
BALANCE SHEET DATA
Current assets Rs m16,299100,015 16.3%   
Current liabilities Rs m7,59474,759 10.2%   
Net working cap to sales %43.218.2 237.5%  
Current ratio x2.11.3 160.4%  
Inventory Days Days65107 60.8%  
Debtors Days Days26110 23.5%  
Net fixed assets Rs m8,62252,350 16.5%   
Share capital Rs m458585 78.2%   
"Free" reserves Rs m20,72267,707 30.6%   
Net worth Rs m21,18070,567 30.0%   
Long term debt Rs m258,472 0.3%   
Total assets Rs m29,137156,994 18.6%  
Interest coverage x755.511.6 6,511.0%   
Debt to equity ratio x00.1 1.0%  
Sales to assets ratio x0.70.9 78.2%   
Return on assets %7.714.3 53.7%  
Return on equity %10.528.1 37.4%  
Return on capital %19.037.7 50.3%  
Exports to sales %0.151.0 0.1%   
Imports to sales %17.518.8 92.7%   
Exports (fob) Rs m1270,927 0.0%   
Imports (cif) Rs m3,52626,193 13.5%   
Fx inflow Rs m5271,015 0.1%   
Fx outflow Rs m14028,799 0.5%   
Net fx Rs m-8842,216 -0.2%   
CASH FLOW
From Operations Rs m3,43617,596 19.5%  
From Investments Rs m-6,991-13,801 50.7%  
From Financial Activity Rs m-619-198 312.1%  
Net Cashflow Rs m-4,1743,597 -116.0%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 8.0 94.3%  
FIIs % 4.9 27.7 17.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.2 232.4%  
Shareholders   85,207 69,601 122.4%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare PFIZER With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Aug 18, 2017 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS